Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"SpliSense","sponsor":"Biotel Limited","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpliSense Secures $28.5 Million in Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"SpliSense"}]

SpliSense

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SpliSense Secures $28.5 Million in Series B Financing

Details:

Proceeds will be used to advance the Company’s pipeline, including its lead Anti Sense Oligonucleotide product, SPL84-23. SPL84-23 to treat the 3849+10kb C->T CFTR mutation, that has showed ability to completely restore CFTR channel function in patient-derived cell cultures.

Lead Product(s): SPL84-23

Therapeutic Area: Genetic Disease Product Name: SPL84-23

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Biotel Limited

Deal Size: $28.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 13, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY